Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | KIF11 | P52732 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8130441 | 0.83 | KIF11 (0.33) | GABRA1GABRB2KIF11 | |
| SCHEMBL13010764 | 0.83 | KIF11 (0.33) | KIF11 | |
| SCHEMBL20933012 | 0.83 | MAPK14 (0.32) | GABRA1GABRB2MAPK14 | |
| SCHEMBL25532127 | 0.81 | GABRA1 (0.30) | GABRA1GABRB2 | |
| SCHEMBL24654885 | 0.80 | — | — | |
| SCHEMBL7379691 | 0.78 | KIF11 (0.31) | KIF11 | |
| SCHEMBL19187341 | 0.77 | GABRA1 (0.33) | GABRA1GABRB2POLBALDH1A1HPGD | |
| SCHEMBL25529751 | 0.77 | — | — | |
| SCHEMBL21163392 | 0.75 | — | — | |
| SCHEMBL10022930 | 0.74 | CES2 (0.36) | MAPK14ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 149 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3428202-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2019-01-16 | — | — | EP | claimed |
| US-9611348-B2 | Process of producing polyolefins using metallocene polymerization catalysts and copolymers therefrom | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2017-04-04 | — | — | US | claimed |
| EP-2984111-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | ExxonMobil Chemical Patents Inc. (US) | 2016-02-17 | — | — | EP | claimed |
| US-20140316085-A1 | Process of Producing Polyolefins Using Metallocene Polymerization Catalysts and Copolymers Therefrom | EXXONMOBIL CHEMICAL PATENTS INC. | 2014-10-23 | — | — | US | claimed |
| WO-2014169017-A1 | PROCESS OF PRODUCING POLYOLEFINS USING METALLOCENE POLYMERIZATION CATALYSTS AND COPOLYMERS THEREFROM | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2014-10-16 | — | — | WO | claimed |
| WO-2004107859-A2 | NOVEL HERBAL MOSQUITO REPELLENT COMPOSITIONS | IYER GANESH NATRAJAN (IN) | 2004-12-16 | — | — | WO | claimed |
| US-20040223998-A1 | Insect repellent | IYER GANESH NATRAJAN (IN) | 2004-11-11 | — | — | US | claimed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | CULLGEN (SHANGHAI), INC. (CN) | 2024-02-29 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-20240026358-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2024-01-25 | — | — | US | disclosed |
| US-11813330-B2 | Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents | THERALASE TECHNOLOGIES, INC. (CA) | 2023-11-14 | — | — | US | disclosed |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | VENTYX BIOSCIENCES, INC. | 2023-11-02 | — | — | US | disclosed |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | 7TM PHARMA A/S (DK) | 2009-04-23 | — | — | US | disclosed |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | S*BIO PTE LTD. (SG) | 2009-03-19 | — | — | US | disclosed |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | METHYLGENE INC. | 2008-11-13 | — | — | US | disclosed |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | SGX PHARMACEUTICALS, INC. (US) | 2008-10-23 | — | — | US | disclosed |
| US-7399765-B2 | Substituted diazabicycloalkane derivatives | ABBOTT LABORATORIES (US) | 2008-07-15 | — | — | US | disclosed |
| WO-2007107758-A1 | ANTIBACTERIAL AGENTS | PROLYSIS LTD (GB) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040223998-A1 | Insect repellent | LSS, BCHE, L3MBTL4 | GABRA1 2413/4885GABRB2 1978/4885POLB 4194/4885 |
| US-20080280925-A1 | Amines as Small Molecule Inhibitors | CARM1, PRMT1, PRMT3 | GABRA1 3885/4885GABRB2 4230/4885POLB 1132/4885 |
| US-20090075999-A1 | OXYGEN LINKED PYRIMIDINE DERIVATIVES | DPYD, TK2, TK1 | GABRA1 4737/4885GABRB2 4642/4885POLB 38/4885 |
| US-20230348478-A1 | TYK2 PSEUDOKINASE LIGANDS | TYK2, JAK2, PTK2B | GABRA1 2283/4885GABRB2 2445/4885POLB 2160/4885 |
| US-20240066136-A1 | MODIFIED PROTEINS AND PROTEIN DEGRADERS | DDB1, DCLRE1A, MDM2 | GABRA1 3613/4885GABRB2 3687/4885POLB 273/4885 |
| US-20080275048-A1 | Substituted Diazabicycloalkane Derivates | CHRNA7, CHRNA1, CHRNA2 | GABRA1 126/4885GABRB2 162/4885POLB 3758/4885 |
| US-11813330-B2 | Sonodynamic therapy using sonodynamically activated coordination complexes of transition metals as sensitizing agents | SON, SSBP1, PIEZO1 | GABRA1 4112/4885GABRB2 4595/4885POLB 384/4885 |
| US-20080261921-A1 | FUSED RING HETEROCYCLE KINASE MODULATORS | MAP3K20, MAP3K19, MAP4K2 | GABRA1 2311/4885GABRB2 1809/4885POLB 2427/4885 |
| US-20090105218-A1 | CRTH2 Receptor Ligands For Therapeutic Use | NR1H2, NR1H3, HRH2 | GABRA1 399/4885GABRB2 445/4885POLB 4251/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.